Ilonov is a preclinical stage biotech developing first-in-class biologics against chronic metabolic diseases, harvesting the potential of muscle secretome to regulate metabolism, a novel & unexplored approach. Our biotherapy specifically preserves & stimulates pancreatic beta cell function by restoring the integrity of the extracellular matrix of the islet niche. Discovered in human muscle post-exercise, our asset has already proven safety & efficacy in preclinical in type 1 and in type 2 diabetes models in vivo. Our goal is to alleviate the burden of daily diabetes management and eliminate severe complications like renal failure, which causes patients to endure expensive and debilitating treatments and reduces their life expectancy.